Relypsa Company Profile (NASDAQ:RLYP)

Analyst Ratings

Consensus Ratings for Relypsa (NASDAQ:RLYP) (?)
Ratings Breakdown: 6 Hold Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $38.69 (21.03% upside)

Analysts' Ratings History for Relypsa (NASDAQ:RLYP)
Show:
DateFirmActionRatingPrice TargetActions
7/24/2016MizuhoReiterated RatingNeutral$20.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2016HC WainwrightDowngradeBuy -> Neutral$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/21/2016Cantor FitzgeraldSet Price TargetBuy$41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/21/2016Morgan StanleyUpgradeUnderweight -> Equal Weight$9.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/21/2016Citigroup Inc.DowngradeBuy -> Neutral$25.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/21/2016Brean CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/21/2016WedbushReiterated RatingOutperform$51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2016Stifel NicolausReiterated RatingBuy$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2016BTIG ResearchReiterated RatingBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Bank of America Corp.Reiterated RatingBuy$32.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015GuggenheimInitiated CoverageBuy$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2015Nomura Holdings Inc.Reiterated RatingOutperform$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Relypsa (NASDAQ:RLYP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/4/2016Q1($1.46)($1.26)$6.88 million$12.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2016Q415($1.35)($1.40)$7.37 million$11.96 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q3($0.89)($1.24)$6.67 million$6.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015($0.95)($0.95)$0.01 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.87)($0.78)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015Q414($0.68)($0.80)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.61)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.57)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014($0.56)($0.54)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q413($0.50)($0.68)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Relypsa (NASDAQ:RLYP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.61)($1.42)($1.52)
Q2 20162($1.53)($1.43)($1.48)
Q3 20162($1.65)($1.47)($1.56)
Q4 20162($1.65)($1.40)($1.53)
Q1 20171($1.65)($1.65)($1.65)
Q2 20171($1.64)($1.64)($1.64)
Q3 20171($1.62)($1.62)($1.62)
Q4 20171($1.59)($1.59)($1.59)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Relypsa (NASDAQ:RLYP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Relypsa (NASDAQ:RLYP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/7/2016David W J McgirrDirectorSell1,013$19.34$19,591.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Kristine M BallCFOBuy7,000$12.15$85,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Thomas J SchuetzDirectorBuy30,000$13.39$401,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2015Wilhelm StahlSVPSell20,000$28.53$570,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Orbimed Advisors LlcMajor ShareholderSell500,000$27.18$13,590,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Lance BermanSVPSell750$29.50$22,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015John A. OrwinCEOSell15,000$28.28$424,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Lance BermanSVPSell30,000$29.78$893,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015John A. OrwinCEOSell40,000$25.00$1,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2015Orbimed Advisors LlcMajor ShareholderBuy500,000$12.56$6,280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015John A OrwinCEOSell5,000$24.84$124,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Lance BermanSVPSell710$24.77$17,586.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Ronald A KrasnowInsiderSell522$24.75$12,919.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2015Thomas J SchuetzDirectorSell1,000$34.57$34,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015John A OrwinCEOSell33,555$36.42$1,222,073.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Orbimed Advisors LlcMajor ShareholderSell1,457,551$34.13$49,746,215.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Klaus R Dr VeitingerDirectorSell5,834$36.06$210,374.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015Klaus R Dr VeitingerDirectorSell5,832$35.35$206,161.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Kristine M BallCFOSell3,519$40.68$143,152.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2015Ronald A KrasnowInsiderSell10,348$39.00$403,572.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2015Lance BermanSVPSell5,000$38.19$190,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2015Ronald A KrasnowInsiderSell10,000$39.00$390,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2015Klaus R Dr VeitingerDirectorSell5,834$32.12$187,388.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2015Claire LockeyInsiderSell5,000$35.00$175,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2015Kristine M BallCFOSell3,000$36.00$108,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2015Ronald A KrasnowInsiderSell5,000$33.58$167,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Klaus R Dr VeitingerDirectorSell5,834$32.33$188,613.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014Klaus R Dr VeitingerDirectorSell14,169$32.16$455,675.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/20145Am Partners Iii, LlcMajor ShareholderSell589,637$30.04$17,712,695.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Claire LockeyInsiderSell8,000$30.00$240,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Lance BermanSVPSell30,000$25.00$750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Klaus R Dr VeitingerDirectorSell2,500$19.34$48,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Lance BermanSVPSell5,000$22.00$110,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Orbimed Advisors LlcMajor ShareholderSell94,000$25.27$2,375,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/20145Am Partners Ii, LlcMajor ShareholderSell612,540$26.03$15,944,416.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Klaus R Dr VeitingerDirectorSell4,167$23.00$95,841.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2014Wilhelm StahlSVPSell15,785$25.29$399,202.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/20145Am Partners Ii, LlcMajor ShareholderSell433,000$26.51$11,478,830.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Lance BermanSVPSell20,000$25.89$517,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Klaus R Dr VeitingerDirectorSell4,167$27.73$115,550.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/24/2014Lance BermanSVPSell45,000$23.92$1,076,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Klaus R Dr VeitingerDirectorSell4,167$23.12$96,341.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/20135Am Partners Iii, LlcMajor ShareholderBuy372,692$11.00$4,099,612.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013John A OrwinCEOBuy15,000$11.00$165,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Leaf Ventures I L.P. NewInsiderBuy185,978$11.00$2,045,758.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Scott M RocklageDirectorBuy363,328$11.00$3,996,608.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Relypsa (NASDAQ:RLYP)
DateHeadline
07/25/16 06:18 PMRelypsa : Acquisition May Not Be in the Best Interests of RLYP Shareholders
07/25/16 06:18 PMRELYPSA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Relypsa, Inc. (RLYP) …
07/25/16 04:56 PMRelypsa Inc. Acquisition May Not Be in the Best Interests of RLYP Shareholders - [PR Newswire] - NEW YORK, July 25, 2016 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Relypsa Inc. ("RLYP" or the "Company") in connection with the proposed acquisition of the Company by Galenica Group ("Galenica"). WeissLaw is investigating whether RLYP's Board acted to maximize shareholder value prior to entering into the agreement. Notably, at least one analyst set a target price of $51.00 per share, or $19 above the offer price. Additionally, the Company recently reported positive financial results, announcing "total revenues for the first quarter 2016 were $12.4 million .
07/25/16 03:42 PMRELYPSA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Relypsa, Inc. (RLYP) Over the Proposed Sale of the Company to Galenica Group - [PR Newswire] - NEW YORK, July 25, 2016 /PRNewswire/ -- Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP , a leading national securities firm headquartered in New York City, is investigating the Board of Directors ...
07/23/16 05:37 PMRelypsa : Galenica to Nab Relypsa in $1.53 Billion Acquisition
07/22/16 11:31 AMU.S. Biotech Relypsa Acquired By Galencia For $1.53B (RLYP) -
07/22/16 10:41 AMRELYPSA, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Galenica May Be Unfair to Shareholders - [Business Wire] - Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Relypsa, Inc.
07/22/16 09:46 AMRyan & Maniskas, LLP Announces Investigation of Relypsa, Inc. - [PR Newswire] - WAYNE, Pa., July 22, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Relypsa, Inc. ("Relypsa" or the "Company") (NASDAQ: ...
07/22/16 09:04 AMGalenica to Acquire Relypsa (RLYP) for $32/Share
07/22/16 09:04 AMSHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Relypsa, Inc. -RLYP
07/22/16 09:04 AMWainwright Says Relypsa Takeout Price Is Fair
07/22/16 09:04 AMRelypsa Inc. (RLYP) Soared To An 11-Month High After Merger
07/22/16 09:04 AMGalenica to Nab Relypsa (RLYP) in $1.53 Billion Acquisition
07/22/16 06:09 AMRelypsa downgraded by H.C. Wainwright -
07/21/16 06:28 PMRelypsa, Inc. (RLYP) – Brean Capital Updates Rating And Raises Price Target
07/21/16 06:28 PMWedbush Sees Room For Anther Relypsa (RLYP) Bidder
07/21/16 06:28 PMWhy the Relypsa Merger Is a Great Idea
07/21/16 06:28 PMRelypsa Inc. (RLYP) Has Soared To An 11-Month High After Bought By Galenica
07/21/16 04:12 PMWhy eBay Inc (EBAY), Qualcomm, Inc. (QCOM) and Relypsa Inc (RLYP) Are 3 of Today’s Best Stocks - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips On a rough day for stocks, earnings and a takeover lifted EBAY, QCOM and RLYP to the top stocks of the day club. The post Why eBay Inc (EBAY), Qualcomm, Inc. (QCOM) and Relypsa Inc (RLYP) Are 3 of Today’s Best Stocks appeared first on InvestorPlace.
07/21/16 04:00 PMHere Are Some Small-Cap Pharma M&A Targets After Relypsa Deal -
07/21/16 10:02 AMRelypsa Inc: RLYP Stock Pops 60% on Galenica Buyout Bid - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Relypsa Inc (RLYP) stock is coming alive Thursday morning after Galenica offered to buy it for $1.53 billion to get its hands on Veltassa. The post Relypsa Inc: RLYP Stock Pops 60% on Galenica Buyout Bid appeared first on InvestorPlace.
07/21/16 09:00 AMRelypsa, Inc. (RLYP) - Citigroup Updates Rating And Raises Price Target - Finance Daily
07/21/16 09:00 AMHC Stocks Watchful: Relypsa Inc (NASDAQ:RLYP), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - share market updates (press release)
07/21/16 03:30 AMPeninsula biotech's $1.5 billion buyout nearly triple IPO price - Nine months after Relypsa Inc. won FDA approval for a kidney disease drug, it has grabbed a Swiss company's $1.5 billion buyout offer, the companies said late Wednesday. The $32-per-share deal between Berne-based Galencia Group (SIX: GALN) and Relypsa (NASDAQ: RLYP) is nearly triple the price of the Redwood City company's late 2013 IPO. The all-cash deal, expected to close in the third quarter, will give Galencia's Vifor Pharma unit worldwide control of Veltassa, a drug designed for chronic kidney…
07/20/16 07:00 PMCan Relypsa, Inc. (NASDAQ:RLYP) Keep Up with Analyst Expectations? - Investor Newswire
07/20/16 09:00 AMEarnings Focus and Crowd Sourced Sentiment Review for Relypsa, Inc. (NASDAQ:RLYP) - TGP
07/20/16 09:00 AMStocks within Analysts Spotlight: Anthem, Inc. (NYSE:ANTM) , Relypsa, Inc. (NASDAQ:RLYP) - Street Updates
07/20/16 09:00 AMHC Stocks Vigilant: Relypsa Inc (NASDAQ:RLYP), St. Jude Medical, Inc. (NYSE:STJ) - share market updates (press release)
07/19/16 07:07 AMHC Stocks Buzzer: Relypsa Inc (NASDAQ:RLYP) Mast Therapeutics Inc (NYSEMKT:MSTX) - share market updates (press release)
07/19/16 07:07 AMAnalysts Tips to Monitor: Abbott Laboratories (NYSE:ABT) , Relypsa, Inc. (NASDAQ:RLYP) - Street Updates
07/19/16 07:07 AMActive biotech company shares in the news: Relypsa, Inc. (NASDAQ:RLYP), Anavex Life Sciences Corp. (NASDAQ ... - The Voice Registrar
07/19/16 07:07 AMBrean Capital Weighs In On Relypsa Inc (RLYP) Following Call with Management - Smarter Analyst
07/18/16 03:15 PMRelypsa Announces New Employment Inducement Grants - [GlobeNewswire] - REDWOOD CITY, Calif., July 18, 2016-- Relypsa, Inc., a biopharmaceutical company, today announced that on July 5, 2016, the compensation committee of the company’ s board of directors granted 2 new employees ...
07/17/16 10:14 AMRelypsa Inc: Could Resume Its Upside To $25
07/14/16 06:25 PMRelypsa: Inflection Point For Veltassa? - Seeking Alpha
07/13/16 09:02 AMHC Stocks Growth: Zoetis Inc (NYSE:ZTS), Relypsa Inc (NASDAQ:RLYP) - share market updates (press release)
07/13/16 09:02 AMRelypsa Inc Realized Volatility Hits Elevated Level - CML News
07/13/16 09:02 AMBrean Capital Bullish on Relypsa Inc (RLYP) on Solid Veltassa Prescription Numbers - Smarter Analyst
07/13/16 09:02 AMRelypsa Inc (RLYP) Headed for Soaring Growth via Veltassa Success - Bidness ETC
07/12/16 06:24 PM'Steady Growth' For Relypsa's Veltassa Launch
07/12/16 06:24 PMRelypsa (RLYP): June Data Could Indicate a Growth Inflection Point - Brean Capital
07/12/16 06:24 PMRelypsa Inc (RLYP) Breaks Out on Drug Data
07/12/16 10:33 AMJune Data On Relypsa's Veltassa 'Very Encouraging'
07/11/16 03:07 PMRELYPSA INC Files SEC form 8-K, Other Events -
07/10/16 05:25 PMRelypsa, Inc. (NASDAQ:RLYP) Broker Price Targets For The Coming Week - Fiscal Standard
07/09/16 05:31 PMJhl Capital Group LLC Increased Relypsa INC (NASDAQ:RLYP) by $9.75 Million as Shares Declined - Press Telegraph
07/07/16 08:57 AMInsiders Increasing Positions in: Relypsa, Inc. (NASDAQ:RLYP) - Press Telegraph
07/07/16 08:57 AMAnalysts Review of Stocks: Medivation, Inc. (NASDAQ:MDVN) , Relypsa, Inc. (NASDAQ:RLYP) - Street Updates
07/07/16 08:57 AMRevenue Estimates Analysis: Relypsa, Inc. (NASDAQ:RLYP) - News Oracle
07/06/16 07:30 AMRelypsa to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference - [GlobeNewswire] - REDWOOD CITY, Calif., July 06, 2016-- Relypsa, Inc. today announced that John A. Orwin, president and chief executive officer, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on ...

Social

About Relypsa

Relypsa logoRelypsa, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients' lives and even be life-threatening. The Company's first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia. Hyperkalemia is a life threatening condition defined as abnormally elevated levels of potassium in the blood. Veltassa is a non-absorbed, potassium binding polymer. The active ingredient in Veltassa is a cross-linked polymeric bead that includes calcium as a counterion. Veltassa is a dry powder that is combined with small amounts of water prior to administration. Veltassa is packaged in single-use packets containing approximately 8.4 grams, 16.8 grams or 25.2 grams patiromer, with a recommended starting dose of approximately 8.4 grams patiromer once daily.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RLYP
  • CUSIP:
Key Metrics:
  • Previous Close: $31.97
  • 50 Day Moving Average: $19.70
  • 200 Day Moving Average: $17.66
  • P/E Ratio: N/A
  • P/E Growth: -2.23
  • Market Cap: $1.43B
  • Beta: 1.6
  • Current Year EPS Consensus Estimate: $-5.99 EPS
  • Next Year EPS Consensus Estimate: $-5.03 EPS
Additional Links:
Relypsa (NASDAQ:RLYP) Chart for Monday, July, 25, 2016